News
8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

 Read the full interview:

Download DocumentDokument herunterladenSwitzerland Global EnterpriseSwitzerland Global Enterprise
1.7.21
Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

Read more
19.5.22
Press Release

TOPADUR together with the USZ / UZH was awarded CHF 607 by Innosuisse

Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.

Read more
3.7.20
Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

Read more

Investors

InvestorsNews & Events

About us

VisionHistoryLeadershipBoard of DirectorsResearch Partners

Pipeline

Wound HealingSkin FibrosisOphthalmologyMedical cosmetics
OncologyLung Fibrosis
‍

Contact

info@topadur.com+41 44 755 44 66
Topadur Pharma AG
Grabenstrasse 11A
8952 Schlieren, Switzerland
ImpressumLegal Disclaimer